Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H32BrF3N8O |
Molecular Weight | 609.484 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C=C(C=C1NCCN2CCCC2)C(=O)CCC(F)(F)F)N3CCN(CC3)C4=NC=NC5=C4C(Br)=NN5
InChI
InChIKey=IKBSEBRGSVFUHM-UHFFFAOYSA-N
InChI=1S/C26H32BrF3N8O/c1-17-19(31-6-9-36-7-2-3-8-36)14-18(21(39)4-5-26(28,29)30)15-20(17)37-10-12-38(13-11-37)25-22-23(27)34-35-24(22)32-16-33-25/h14-16,31H,2-13H2,1H3,(H,32,33,34,35)
XL418 is a dual protein kinase B (Akt) and ribosomal protein S6 Kinase (p70 S6K) inhibitor that also acts as an ATP-pocket binder with potential antineoplastic activity. XL418 was involved in phase I clinical trial in patients with solid tumors, however, in Dec 2007, this study was discontinued, due to low drug exposure.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20616901
Unknown
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
OLJ18SRI8A
Created by
admin on Fri Dec 15 16:20:50 GMT 2023 , Edited by admin on Fri Dec 15 16:20:50 GMT 2023
|
PRIMARY | |||
|
56963011
Created by
admin on Fri Dec 15 16:20:50 GMT 2023 , Edited by admin on Fri Dec 15 16:20:50 GMT 2023
|
PRIMARY | |||
|
DB05204
Created by
admin on Fri Dec 15 16:20:50 GMT 2023 , Edited by admin on Fri Dec 15 16:20:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL3544935
Created by
admin on Fri Dec 15 16:20:50 GMT 2023 , Edited by admin on Fri Dec 15 16:20:50 GMT 2023
|
PRIMARY | |||
|
871343-09-8
Created by
admin on Fri Dec 15 16:20:50 GMT 2023 , Edited by admin on Fri Dec 15 16:20:50 GMT 2023
|
PRIMARY | |||
|
C68963
Created by
admin on Fri Dec 15 16:20:50 GMT 2023 , Edited by admin on Fri Dec 15 16:20:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY